Navigation Links
Selexis Launches Biosimilar Cell Line Development Program
Date:3/30/2009

As the world leader of cell line manufacturing, Selexis is now offering a portfolio of cell lines expressing biosimilar recombinant protein drugs with added characterization services

GENEVA, March 31 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company offering technologies and services for the rapid development of high-performance stable production cell lines announced today an expanded offering focusing on the biosimilar market segment. Under the new program, Selexis will offer clients the contract development of high producing mammalian cell lines expressing biosimilars, including expanded characterization capabilities. Selexis scientists have already demonstrated, using the Selexis SURE Cell Line Development(SM) Platform, the production of biosimilars proteins at levels as much as 50 fold greater than the currently marketed drugs. The Selexis' SURE Cell Line Development(SM) platform combines Selexis' Intellectual Property rights (e.g. novel genetic elements DNA sequences and transfection procedures) with its cell culture know-how for the rapid development of biosimilars products.

Dr. Igor Fisch, President and CEO of Selexis, commented:

"We feel it is a very important step towards the creation of a global company offering fully integrated services to our client worldwide by including biosimilar expressing cell lines Importantly, in support of this new offer, we are also expanding our support of product characterization capabilities which will further enhance the value of this package".

By combining proprietary technologies with know-how on a fully integrated platform, Selexis can provide top performance cell lines in a industry-known and accepted package.

About Biosimilars:

Biosimilars or Follow-on biologics are terms used to describe officially approved new versions of innovator biopharmaceutical products, following patent expiry.

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development(SM) process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.


'/>"/>
SOURCE Selexis
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. First Application to Fight High Cholesterol Launches on the iPhone and iPod Touch
2. Merck Serono Launches Strategic Venture Capital Fund
3. Boston Scientific Launches New Coronary Imaging Catheter
4. LUMEDX Launches New Interventional Radiology Software
5. Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition
6. StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies
7. PDHI Launches Short Form of Its ConXus Profile Health Assessment
8. Zymes Omega Solutions Bottles and Launches the Worlds First Omega-3 Enhanced Water
9. Irvine Scientific Launches IS CHO-CD XP(TM)
10. Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers
11. Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... ... containing an organic compound called fulvic acid that farms, greenhouses and hydroponics operations ... grow cannabis are among the fastest growing segments of customers using this high ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome ... expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with ...
(Date:1/12/2017)... ... ... Huffman Engineering, Inc. , a leader in control systems integration, today announced ... as a chemical engineer. In his new role, Beck will use his extensive ... manufacturing and water/wastewater industries. , Prior to joining Huffman Engineering, Beck served for nine ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
Breaking Biology Technology:
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
(Date:12/22/2016)... 2016 SuperCom (NASDAQ:   ... the e-Government, Public Safety, HealthCare, and Finance sectors announced today that ... selected to implement and deploy a community-based supportive services program to ... , further expanding its presence in the state. ... This new program, which is ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
Breaking Biology News(10 mins):